TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9530462

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8082354

Group type: EXPERIMENTAL
Intervention: Spacer device with inhaled beta-agonist at discharge
Number of subjects: 84

Group type: COMPARATOR
Intervention: Inhaled or oral beta-agonists without a spacer device
Number of subjects: 84
Study: 2683547

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: No H2 receptor antagonist (Control)
Number of subjects: 17
Study: 747177

Group type: EXPERIMENTAL
Intervention: Naltrexone 25 mg first-day dose
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg first-day dose
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Naltrexone 150 mg first-day dose
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Naltrexone maintenance regimen in Group A (5 times weekly)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Naltrexone maintenance regimen in Group B (3 times weekly)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Naltrexone maintenance regimen in Group C (2 times weekly)
Number of subjects: 42
Study: 31987769

Group type: COMPARATOR
Intervention: High dose (HD) group received 4 mg of folic acid daily from the first 3 months of pregnancy until the entire pregnancy.
Number of subjects: 1576

Group type: EXPERIMENTAL
Intervention: Low dose (LD) group received 0.4 mg of folic acid daily from the first 3 months of pregnancy until the entire pregnancy.
Number of subjects: 1576

Group type: COMPARATOR
Intervention: High dose (HD) group with compliance >50%.
Number of subjects: 1576
Study: 30407046

Group type: EXPERIMENTAL
Intervention: Peer-led Seeking Safety (PL-SS)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Clinician-led Seeking Safety (CL-SS)
Number of subjects: 278
Study: 28237842

Group type: EXPERIMENTAL
Intervention: Treatment (mobile application)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (standard risk counseling)
Number of subjects: 84
Study: 26173038

Group type: EXPERIMENTAL
Intervention: Automated SMS program supplementing a 25-session youth development program
Number of subjects: 221
Study: 23990989

Group type: EXPERIMENTAL
Intervention: Brief outreach academic detailing intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no specific intervention beyond receiving guidelines)
Number of subjects: 46
Study: 21248209

Group type: EXPERIMENTAL
Intervention: Internet-based telerehabilitation program
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional outpatient physical therapy
Number of subjects: 65
Study: 19793643

Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alpha‐2b
Number of subjects: 299

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Positive RT‐PCR sample
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Negative RT‐PCR sample
Number of subjects: 299
Study: 17476525

Group type: EXPERIMENTAL
Intervention: Active muscle stretch (15, 25, and 35 degrees at a velocity of 60 degrees s(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Active muscle stretch
Number of subjects: 15
Study: 15100594

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Patient education alone
Number of subjects: 45
Study: 11706977

Group type: EXPERIMENTAL
Intervention: Convergence retraction nystagmus (CRN)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 1
Study: 9340922

Group type: EXPERIMENTAL
Intervention: Supraphysiologic magnesium administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 8432466

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3319722

Group type: EXPERIMENTAL
Intervention: Oxiconazole cream, applied once daily
Number of subjects: 0
Study: 30384034

Group type: EXPERIMENTAL
Intervention: Tobacco control advocacy capacity-building programme
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Control group (public health undergraduate students from 11 universities)
Number of subjects: 1245
Study: 27575834

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 50 J dose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 10 J dose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 10 J and 50 J doses
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 30 J dose
Number of subjects: 28
Study: 24689258

Group type: EXPERIMENTAL
Intervention: Cognitive load (high load conditions with a concurrent working memory task using auditory stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (steady lane position without cognitive load)
Number of subjects: 0
Study: 22278428

Group type: EXPERIMENTAL
Intervention: HyEx60 (60 min of continuous exercise at 90% lactate threshold in hypoxia)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hy5:5 (intermittent exercise at 120% lactate threshold in hypoxia)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normoxia (intermittent exercise at 120% lactate threshold in normoxia)
Number of subjects: 8
Study: 20227726

Group type: EXPERIMENTAL
Intervention: 2‐year recreational physical activity program (3 90‐minute sessions per week for 28 weeks each year)
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: 2‐year recreational physical activity program
Number of subjects: 1044
Study: 18381502

Group type: EXPERIMENTAL
Intervention: Provider- and peer-delivered intervention (based on the 5A model) consisting of brief counseling and follow-up visits/calls.
Number of subjects: 2711

Group type: COMPARATOR
Intervention: Usual care control condition.
Number of subjects: 2711
Study: 16630310

Group type: EXPERIMENTAL
Intervention: Active occlusal interference
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dummy interference
Number of subjects: 11

Group type: COMPARATOR
Intervention: Interference-free condition
Number of subjects: 11
Study: 14618643

Group type: EXPERIMENTAL
Intervention: Wheeze group
Number of subjects: 390

Group type: COMPARATOR
Intervention: Chest-Colds group
Number of subjects: 390

Group type: COMPARATOR
Intervention: Cough Alone group
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study: 11006890

Group type: EXPERIMENTAL
Intervention: Global Coronary Risk Score (derived from 10-year follow-up mortality)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global Coronary Risk Score
Number of subjects: 0
Study: 8792045

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 300 mg/week
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 600 mg/week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 16
Study: 1616829

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 306
Study: 3881907

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30064297

Group type: EXPERIMENTAL
Intervention: Optimal Load Training (OLT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Modified Complex Training (MCT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 18
Study: 29079411

Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 orally twice daily, days 1-14, every 21 days)
Number of subjects: 1564

Group type: COMPARATOR
Intervention: S-1 (40 mg/m2 orally twice daily, days 1-28, every 42 days)
Number of subjects: 1564

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 1564

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Capecitabine and S-1
Number of subjects: 1564
Study: 26362898

Group type: EXPERIMENTAL
Intervention: IFNB‐1b
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 362
Study: 25236776

Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention (REACH website access, pedometer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (paper diary, generic incremental step goals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention
Number of subjects: 0
Study: 22341040

Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programme alone (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comprehensive rehabilitation programme combined with acetaminophen 1g three times a day (group B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of VAS score variations between groups A and B
Number of subjects: 44
Study: 20356555

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (LH)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low-dose unfractionated heparin (LUFH)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose low molecular weight heparin (LLMWH)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Low molecular weight unfractionated heparin (LLMWUFH)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-dose heparin (HH)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-dose low molecular weight heparin (HLMWH)
Number of subjects: 38
Study: 19045970

Group type: EXPERIMENTAL
Intervention: Dietary-negative affect subtype
Number of subjects: 131

Group type: COMPARATOR
Intervention: Dietary subtype
Number of subjects: 131
Study: 16287765

Group type: EXPERIMENTAL
Intervention: Hard intensity - high frequency (HardI-HiF)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Hard intensity - low frequency (HardI-low-frequency)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Moderate intensity - high frequency (moderate-intensity-HiF)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Physician advice (control group)
Number of subjects: 492
Study: 12114150

Group type: EXPERIMENTAL
Intervention: Checklist-oriented group (Group 1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Global ratings-oriented group (Group 2)
Number of subjects: 57
Study: 10633209

Group type: EXPERIMENTAL
Intervention: 0.5 mg of iron per day (nutritional supplement made from bovine blood)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study: 7797897

Group type: EXPERIMENTAL
Intervention: Bivalent live attenuated influenza A virus vaccine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study: 2368963

Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone (O3)
Number of subjects: 10

Group type: COMPARATOR
Intervention: filtered air
Number of subjects: 10
Study: 756057

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31494443

Group type: EXPERIMENTAL
Intervention: Perceived substance use by friends outside of school
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Perceived substance use by brothers or sisters
Number of subjects: 1285

Group type: EXPERIMENTAL
Intervention: Perceived substance use by friends online
Number of subjects: 1285
Study: 28803082

Group type: EXPERIMENTAL
Intervention: Outlook intervention
Number of subjects: 221

Group type: COMPARATOR
Intervention: Relaxation meditation (RM)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 221
Study: 26146798

Group type: EXPERIMENTAL
Intervention: Child Health Utility 9D (CHU9D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: d3mfs+D3MFS index score
Number of subjects: 80
Study: 23141383

Group type: EXPERIMENTAL
Intervention: 50% increased risk for AD
Number of subjects: 50

Group type: COMPARATOR
Intervention: general age-related risk for AD
Number of subjects: 50
Study: 21658476

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia (CBT-I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study: 19705924

Group type: EXPERIMENTAL
Intervention: Bilastine 5 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 310
Study: 16500251

Group type: EXPERIMENTAL
Intervention: Johns Hopkins Antibiotic Guide (JHABX) on the RIM Blackberry PDA
Number of subjects: 12

Group type: COMPARATOR
Intervention: non‐PDA group
Number of subjects: 12
Study: 15533851

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate plus hydralazine
Number of subjects: 1050
Study: 11575443

Group type: EXPERIMENTAL
Intervention: 200 ml water containing 10 mg Cu/L (as copper sulfate)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 200 ml distilled water
Number of subjects: 31
Study: 9569658

Group type: EXPERIMENTAL
Intervention: Bilingual Hong Kong students (Study 1)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Undergraduates of European and Chinese ancestry living in Canada (Study 2)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Peer ratings of Chinese students (Study 3)
Number of subjects: 894

Group type: EXPERIMENTAL
Intervention: Cultural standards for judging traits (Study 3)
Number of subjects: 894
Study: 8118750

Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) - 2 mg 17 beta-estradiol plus 1 mg norethisterone daily for 1 year
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nandrolone Decanoate (ND) - 50 mg i.m. every 3 weeks for 1 year
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo for HRT
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo for ND
Number of subjects: 66
Study: 3415895

Group type: EXPERIMENTAL
Intervention: MHS(B) - morphine hydrogel suppository with high initial release rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MHS(S) - morphine hydrogel suppository with constant release rate
Number of subjects: 0
Study: 31209260

Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling
Number of subjects: 62
Study: 29231336

Group type: EXPERIMENTAL
Intervention: Acupuncture based on the theory of 'the compatibility of the five meridians' in Huxiang
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional triple drugs (omeprazole, amoxicillin and clarithromycin) for Hp positive patients, and omeprazole for Hp negative patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25872149

Group type: EXPERIMENTAL
Intervention: Single-dose treatment of AM-101
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three doses of AM-101 over 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three injections of AM-101 over 3 consecutive days
Number of subjects: 0
Study: 23715452

Group type: EXPERIMENTAL
Intervention: Gum retraction by Roeko stay put non impregna cords
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Shoulders prepared at the gingival margin
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Shoulder located subgingivally
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (40 teeth)
Number of subjects: 53
Study: 22019971

Group type: EXPERIMENTAL
Intervention: VR treadmill training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional treadmill training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study: 18587524

Group type: EXPERIMENTAL
Intervention: Depressive syndrome (defined as depressed mood and three additional depressive symptoms)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Control condition (without depressive symptoms)
Number of subjects: 838
Study: 16494543

Group type: EXPERIMENTAL
Intervention: Two-trocar laparoscopic-assisted appendectomy
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Conversion of initial procedure (due to excessive body weight)
Number of subjects: 83
Study: 12956495

Group type: EXPERIMENTAL
Intervention: IMZ two-stage implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: ITI one-stage implants
Number of subjects: 40
Study: 10939551

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 256

Group type: COMPARATOR
Intervention: Fosphenytoin
Number of subjects: 256
Study: 9553237

Group type: EXPERIMENTAL
Intervention: Fentanyl 150 micrograms
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Lidocaine 60 mg
Number of subjects: 112

Group type: COMPARATOR
Intervention: Normal Saline (Placebo)
Number of subjects: 112
Study: 8368558

Group type: EXPERIMENTAL
Intervention: Halothane (0.5%-1%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enflurane (1.5%-2%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.2%-1.8%)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (6.0 mg.kg‐1 x h‐1 propofol)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between halothane and TIVA
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between enflurane and TIVA
Number of subjects: 80
Study: 2947345

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (Provera) 20 mg orally thrice daily for one month
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 11
Study: 30257641

Group type: EXPERIMENTAL
Intervention: As concentration >=0.02 mg/kg
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Ni concentration >=0.1232 mg/kg
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Se concentration >=0.02 mg/kg
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Fe concentration >=6.9153 mmol/L
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Ni concentration >=0.0965 mg/kg
Number of subjects: 833
Study: 28870472

Group type: EXPERIMENTAL
Intervention: High β‐glucan barley (4.4 g/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: β‐glucan‐free barley (placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High β‐glucan barley (4.4 g/d) in subgroup with VFA ≥100 cm2
Number of subjects: 100

Group type: COMPARATOR
Intervention: β‐glucan‐free barley (placebo) in subgroup with VFA ≥100 cm2
Number of subjects: 100
Study: 26125415

Group type: EXPERIMENTAL
Intervention: mobile health+CarePartner (mHealth+CP)
Number of subjects: 369
Study: 24908523

Group type: EXPERIMENTAL
Intervention: Subcuticular suture with No '1' polyfilament (petcryl)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Intermittent suture with nylon 2‐0
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both groups (Subcuticular and Intermittent)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Prolonged rupture of membrane >18 hours
Number of subjects: 138
Study: 20350051

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin salt tablet 150 mg twice daily for 14 consecutive days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18486720

Group type: EXPERIMENTAL
Intervention: Diet and medication therapy to lower urine supersaturation
Number of subjects: 0
Study: 16904419

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) with Loestrin 1/20
Number of subjects: 15

Group type: COMPARATOR
Intervention: Loestrin 1/20
Number of subjects: 15
Study: 12462959

Group type: EXPERIMENTAL
Intervention: Stress management program
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Hierarchical regression model
Number of subjects: 63
Study: 10509788

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYCLO) at a dose of 1200 mg/m2
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS) at a dose of 5 g/m2
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both CYCLO and IFOS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYCLO)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 61
Study: 8948244

Group type: EXPERIMENTAL
Intervention: Hansson hook‐pins
Number of subjects: 47

Group type: COMPARATOR
Intervention: Charnley hip replacement
Number of subjects: 47
Study: 1781536

Group type: EXPERIMENTAL
Intervention: 150 ml of clear fluid 1.5‐2 hours before anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fasted from midnight the night before
Number of subjects: 100
Study: 6792382

Group type: EXPERIMENTAL
Intervention: Protein-containing solution with hypertonic glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protein-free solution
Number of subjects: 0
Study: 30831601

Group type: EXPERIMENTAL
Intervention: Current use of soy supplements
Number of subjects: 76442
Study: 29170461

Group type: EXPERIMENTAL
Intervention: Described‐High group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Described‐Low group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pupil dilation and behavioral data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin conductance responses and pupil dilation
Number of subjects: 0
Study: 27256356

Group type: EXPERIMENTAL
Intervention: nasally administered oxytocin
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study: 24393351

Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 21928106

Group type: EXPERIMENTAL
Intervention: VC-APS arm (vinorelbine and cisplatin combined with Astragalus polysaccharide)
Number of subjects: 136

Group type: COMPARATOR
Intervention: VC arm (vinorelbine and cisplatin)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: VC-APS arm
Number of subjects: 136

Group type: COMPARATOR
Intervention: VC arm
Number of subjects: 136
Study: 19501409

Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin for 3 days before injection
Number of subjects: 129

Group type: COMPARATOR
Intervention: Povidone-iodine (PVI) alone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin in combination with PVI
Number of subjects: 129